New test for Lyme disease is not reliable To determine whether someone has Lyme disease, doctors in the Netherlands often use antibody tests. For some time now, so-called cellular tests have been available on the market.
Ten years of Tick Radar 80,000 tick bite reports; chances of being bitten highest in Drenthe After recording 80,000 tick bites in 10 years via Tekenradar.nl, we now know that you are most likely to be bitten by a tick in Drenthe. Quickly removing the tick halves the chance of contracting Lyme disease.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Better monitoring of RSV thanks to new European project RIVM and Nivel contribute to building a European RSV monitoring network. Through the network, European health institutions and laboratories will exchange data on the spread of RSV. This will help us to better monitor the virus.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.